A Massachusetts overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
Massachusetts adult obesity rose from 24.4% in 2020 to 27.0% in 2024, per CDC BRFSS prevalence estimates: a nearly three-point jump in four years 1.
The bigger change in Massachusetts this year was on the coverage side, and roughly 22,000 people found out about it at the pharmacy counter.
MassHealth ended coverage of GLP-1 and other anti-obesity medications for weight-loss-only use effective July 1, 2026, dropping Wegovy, Zepbound, Saxenda, Xenical, and phentermine-based agents from the covered list for that indication 34. Coverage is unchanged when the same drugs are prescribed for an approved indication other than obesity, most commonly type 2 diabetes 3.
The state estimates the change affects at least 22,000 MassHealth members and will save roughly 5 million a year 34. This is a rollback, not a state that never covered these drugs: MassHealth had covered anti-obesity GLP-1s without extra qualifying conditions since January 2024 3. Boston.com described that prior policy as making Massachusetts one of just 14 states covering these drugs without added qualifying conditions; WBUR, citing KFF, puts the count at 13 34.
MassHealth's Assistant Secretary, Dr. Ryan Schwarz, called the prior policy "unsustainable" and said the state hopes to restore coverage in the future if costs come down 3.
A sourcing note worth stating plainly: mass.gov and MassHealth pages returned HTTP 403 to every automated fetch during this review, so no first-party MassHealth document could be retrieved. The facts above are corroborated by two independent local-news accounts that agree on the drug list, the July 1, 2026 effective date, the 22,000-member impact, and the 5 million figure 34.
MassHealth enrollees who lost coverage are now looking at list prices of roughly ,000 to ,300 per month, per Boston.com's reporting 4.
Astra's price in Massachusetts is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no Massachusetts-specific price or discount, and there was none before July 1 either.
For context on who is exposed: Massachusetts has one of the country's lowest uninsured rates at 2.8%, against a median household income of 04,828 (ACS 2024 1-year, MOE ± ,650) 5. Losing a covered benefit, not lacking insurance, is the failure mode here.
TODO — not yet verified. Massachusetts-specific telehealth prescribing rules, including initial-exam requirements, controlled-substance telehealth rules, and cross-state licensure reciprocity, were not confirmed in this pass (mass.gov returned HTTP 403 to automated requests, consistent with the MassHealth gap above). This page does not present any of those as settled fact.
Check current requirements with the Massachusetts Board of Registration in Medicine: mass.gov/orgs/board-of-registration-in-medicine.
Astra serves patients in all 50 states, Massachusetts included, across a population of 7,136,171 (Census Vintage 2024 estimate) 2. Visits and refills are handled online, with medication from a state-licensed US compounding pharmacy.
Springfield has its own page below.
Astra treats patients in Massachusetts through state-licensed physicians.
City-level detail for Massachusetts.
No — not for weight loss alone, as of July 1, 2026. MassHealth ended coverage of Wegovy, Zepbound, Saxenda, Xenical, and phentermine-based drugs for weight-loss-only use, affecting an estimated 22,000 members. Coverage continues unchanged when the same drug is prescribed for an approved indication other than obesity, such as type 2 diabetes (sources: WBUR, June 23, 2026; Boston.com, June 27, 2026).
The state says the prior policy — in place since January 2024 without added qualifying conditions — had become too costly to sustain. MassHealth's Assistant Secretary, Dr. Ryan Schwarz, called it "unsustainable" and said the state hopes to restore coverage in the future. The change is projected to save Massachusetts about $15 million a year (WBUR, June 23, 2026).
List prices run roughly $1,000–$1,300 a month: Boston.com reported Wegovy at more than $1,300/month and Zepbound at around $1,000/month (manufacturer savings programs can lower these for some patients, but list price is what MassHealth members who lost coverage are now facing).
Astra's price is the same in Massachusetts as everywhere else in the country — $68/month for semaglutide or $118/month for tirzepatide, billed at $816 or $1,416 per year on a 12-month plan. There is no Massachusetts-specific discount. But compared with the $1,000–$1,300/month list prices MassHealth enrollees now face after losing coverage, Astra's flat national rate is dramatically lower for anyone paying out of pocket.
Yes. Astra is licensed to provide GLP-1 telehealth care in all 50 states, including Massachusetts.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.